A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs NY-ESO-1 ISCOMATRIX (Primary) ; Cyclophosphamide
- Indications Malignant melanoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Oct 2009 Planned end date changed from 1 Apr 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 21 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.